Company Filing History:

25 out of 1,035

Children's Medical Center Corporation

patents

1 out of 413

Cincinnati Children's Hospital Medical Center

Years Active: 1997-2011

Loading Chart...

27 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 7867975 - Therapeutic antiangiogenic endostatin compositions (2011-01-11),

2. 7655458 - Nucleic acid molecules encoding endostatin protein and peptide fragments thereof (2010-02-02),

3. 7485439 - Nucleic acids encoding plasminogen fragments and methods of use (2009-02-03),

4. 7365159 - Angiostatin protein (2008-04-29),

5. 7179608 - Therapeutic antiangiogenic compositions and methods (2007-02-20),

6. 7157556 - Deglycosylated kringle 1-3 region fragments of plasminogen and methods of use (2007-01-02),

7. 7101979 - Antibodies to antiangiogenic compositions and methods (2006-09-05),

8. 6949511 - Methods of inhibiting angiogenesis via increasing in vivo concentrations of kringle region fragments of plasminogen (2005-09-27),

9. 6764995 - Endostatin protein and fragments thereof (2004-07-20),

10. 6746865 - Nucleic acids encoding for endostatin protein (2004-06-08),

11. 6630448 - Methods of inhibiting angiogenesis with endostatin protein (2003-10-07),

12. 6607724 - Compositions and methods for inhibiting angiogenesis (2003-08-19),

13. 6544758 - Methods for expressing endostatin protein (2003-04-08),

14. 6521439 - Nucleic acids encoding plasminogen fragments (2003-02-18),

15. 6346510 - Therapeutic antiangiogenic endostatin compositions (2002-02-12),

Title: The Legacy of Inventor M Judah Folkman

Introduction: M Judah Folkman, a pioneering inventor hailing from Brookline, MA (US), made significant contributions to the field of medicine through his groundbreaking innovations.

Latest Patents: While no longer with us, Folkman's patents continue to impact the medical world, with his latest patents focusing on novel approaches to cancer treatment and angiogenesis inhibition.

Career Highlights: Folkman's illustrious career was marked by his revolutionary discovery of angiogenesis inhibitors, which laid the foundation for anti-cancer therapies. His work led to the development of drugs that target blood vessel formation in tumors, ultimately changing the landscape of cancer treatment.

Collaborations: Throughout his career, Folkman collaborated with leading researchers, medical professionals, and pharmaceutical companies to further his research and bring his inventions to life. His collaborative spirit and innovative mindset were instrumental in his success.

Conclusion: M Judah Folkman's legacy as an inventor and medical pioneer is unparalleled, with his work continuing to inspire advancements in cancer research and treatment. His impact on the field of medicine will be felt for generations to come.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com